Literature DB >> 24873794

Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time.

Alin Chirindel1, Krishna C Alluri, Abdel K Tahari, Muhammad Chaudhry, Richard L Wahl, Martin A Lodge, Rathan M Subramaniam.   

Abstract

OBJECTIVE: The objective of this study is to establish the magnitude change and interreader reliability of the liver standardized uptake value corrected for lean body mass (SULmean) in dual-time-point imaging at 1 and 2 hours and 1 and 4 hours. PATIENTS AND METHODS: Early and delayed FDG PET/CT scans were included for 28 patients (13 men and 15 women) who had normal liver by CT or ultrasound. The average uptake time between the early and delayed scans were 55 minutes (range, 44-69 minutes) for pancreatic adenocarcinoma patients (n = 19) and 184 minutes (range, 140-197 minutes) for neurofibromatosis patients (n = 9). A 30-mm-diameter spherical volume of interest was placed within the right lobe of the liver above, below, and at the level of the main portal vein by 2 independent readers. Correlation coefficients, analysis of variance, intraclass correlation coefficient, and Bland-Altman analysis were performed.
RESULTS: The mean liver SULmean was between 1.39 and 1.42 and between 1.28 and 1.3 in early and delayed images, respectively (P = 0.001). There is time-dependent reduction in the mean liver SULmean at 2-hour (7%-8%) and 4-hour uptake time (15%-21%) compared with 1-hour uptake time. The correlation coefficient between delayed uptake time and liver SULmean reduction is 0.39 to 0.41 at the upper aspect of the liver. The intraclass correlation coefficient for 2 readers varied between 0.997 and 0.998 and between 0.995 and 0.999 in early and delayed images, respectively (P = 0.001).
CONCLUSIONS: There is time-dependent reduction of mean liver SULmean, about 7% to 8% within the clinically relevant FDG uptake time, in the same patient with excellent interreader agreement in early and delayed images within the right lobe of the liver. Therefore, liver SULmean could represent a useful reference parameter in quantitative analysis of dual-phase FDG PET/CT in malignancy or atypical infection/inflammatory disease. Furthermore, it may be suitable as a normalization factor in currently available formulae quantifying therapy response on PET imaging.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24873794      PMCID: PMC5413863          DOI: 10.1097/RLU.0000000000000446

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  32 in total

1.  Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging.

Authors:  Michael S Hofman; Nigel C Smeeton; Sheila C Rankin; Tom Nunan; Michael J O'Doherty
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

2.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck.

Authors:  R Hustinx; R J Smith; F Benard; D I Rosenthal; M Machtay; L A Farber; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-10

3.  Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Toshihide Monden; Yasuhiro Sasakawa; Kunihiko Tsutsui; Hisao Wakabayashi; Motoomi Ohkawa
Journal:  Nucl Med Commun       Date:  2005-10       Impact factor: 1.690

4.  18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging.

Authors:  Elizabeth H Dibble; Ana C Lara Alvarez; Minh-Tam Truong; Gustavo Mercier; Earl F Cook; Rathan M Subramaniam
Journal:  J Nucl Med       Date:  2012-04-09       Impact factor: 10.057

5.  Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.

Authors:  Akinori Asagi; Koji Ohta; Junichirou Nasu; Minoru Tanada; Seijin Nadano; Rieko Nishimura; Norihiro Teramoto; Kazuhide Yamamoto; Takeshi Inoue; Haruo Iguchi
Journal:  Pancreas       Date:  2013-01       Impact factor: 3.327

6.  Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake.

Authors:  Jessica M Davison; Al Ozonoff; Heather M Imsande; Gregory A Grillone; Rathan M Subramaniam
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

Review 7.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

8.  Comparison of early and delayed FDG PET for evaluation of biliary stricture.

Authors:  Yoshihiro Nishiyama; Yuka Yamamoto; Naruhide Kimura; Akihiro Miki; Yasuhiro Sasakawa; Hisao Wakabayashi; Motoomi Ohkawa
Journal:  Nucl Med Commun       Date:  2007-12       Impact factor: 1.690

9.  Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h.

Authors:  Bennett B Chin; Edward D Green; Timothy G Turkington; Thomas C Hawk; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2008-11-27       Impact factor: 3.488

10.  Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.

Authors:  V J Lowe; D M DeLong; J M Hoffman; R E Coleman
Journal:  J Nucl Med       Date:  1995-05       Impact factor: 10.057

View more
  9 in total

1.  Impacts of biological and procedural factors on semiquantification uptake value of liver in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging.

Authors:  Mohd Hafizi Mahmud; Abdul Jalil Nordin; Fathinul Fikri Ahmad Saad; Ahmad Zaid Fattah Azman
Journal:  Quant Imaging Med Surg       Date:  2015-10

2.  The extent to which standardized uptake values reflect FDG phosphorylation in the liver and spleen as functions of time after injection of 18F-fluorodeoxyglucose.

Authors:  Georgia Keramida; Constantinos D Anagnostopoulos; A Michael Peters
Journal:  EJNMMI Res       Date:  2017-02-07       Impact factor: 3.138

3.  Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?

Authors:  Dominik Berzaczy; Marius E Mayerhoefer; Amedeo A Azizi; Alexander R Haug; Daniela Senn; Dietrich Beitzke; Michael Weber; Tatjana Traub-Weidinger
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

4.  Propensity score analysis of 18-FDG PET/CT-enhanced staging in patients undergoing surgery for esophageal cancer.

Authors:  N Patel; Kieran G Foley; A G Powell; J R Wheat; D Chan; P Fielding; S A Roberts; W G Lewis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-16       Impact factor: 9.236

5.  Intrapatient variability of 18F-FDG uptake in normal tissues.

Authors:  Mohamed Hosny Mohamed Sayed; Aya Km Abdelnaim; Nsreen Ra Mohamadien
Journal:  J Clin Imaging Sci       Date:  2022-07-08

Review 6.  Does quantification have a role to play in the future of bone SPECT?

Authors:  James C Ross; Dijana Vilić; Tom Sanderson; Stefan Vöö; John Dickson
Journal:  Eur J Hybrid Imaging       Date:  2019-05-03

7.  Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients.

Authors:  Marius E Mayerhoefer; Chiara Giraudo; Daniela Senn; Markus Hartenbach; Michael Weber; Ivo Rausch; Barbara Kiesewetter; Christian J Herold; Marcus Hacker; Matthias Pones; Ingrid Simonitsch-Klupp; Leonhard Müllauer; Werner Dolak; Julius Lukas; Markus Raderer
Journal:  Clin Nucl Med       Date:  2016-02       Impact factor: 7.794

8.  Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer.

Authors:  Christina Baun; Kirsten Falch; Oke Gerke; Jeanette Hansen; Tram Nguyen; Abass Alavi; Poul-Flemming Høilund-Carlsen; Malene G Hildebrandt
Journal:  BMC Med Imaging       Date:  2018-05-09       Impact factor: 1.930

9.  Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT.

Authors:  Sophie E Vollenbrock; Marlies E Nowee; Francine E M Voncken; Alexis N T J Kotte; Lucas Goense; Peter S N van Rossum; Astrid L H M W van Lier; Stijn W Heijmink; Annemarieke Bartels-Rutten; Frank J Wessels; Berthe M P Aleman; Luc Dewit; Linda G W Kerkmeijer; Edwin P M Jansen; Martijn Intven; Irene M Lips; Gert J Meijer; Jasper Nijkamp
Journal:  Adv Radiat Oncol       Date:  2019-04-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.